Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

208
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
208
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

203
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
203
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

189
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
189
Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

569
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
569
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

179
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
179
Lewis Acids and Bases02:33

Lewis Acids and Bases

48.5K
In 1923, G. N. Lewis proposed a generalized definition of acid-base behavior in which acids and bases are identified by their ability to accept or to donate a pair of electrons and form a coordinate covalent bond.
A coordinate covalent bond (or dative bond) occurs when one of the atoms in the bond provides both bonding electrons. For example, a coordinate covalent bond occurs when a water molecule combines with a hydrogen ion to form a hydronium ion. A coordinate covalent bond also results when...
48.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-omics and spatial proteomic profiling reveal novel AGXT2<sup>-</sup> PYCR3<sup>-</sup> macrophages and their phenotypes in metabolic dysfunction-associated steatotic liver disease.

Genome medicine·2026
Same author

Technical and tactical performance of major Asian professional football leagues: a comparative analysis of 14,115 matches across six seasons.

Biology of sport·2026
Same author

Automated risk scoring for venous thromboembolism using large language models with expert knowledge-augmented prompting: a multicenter validation study.

NPJ digital medicine·2026
Same author

The One-Step Incorporation of Boron-10 Atom into Prostate Cancer-Targeted Fluorophores for Visualizing In Vivo Boron-10 Delivery and Intratumoral Distribution with Cellular Resolution.

Journal of medicinal chemistry·2026
Same author

Effects of different polysaccharides on the anti-Retrogradation of buckwheat Wantuan.

Food chemistry: X·2026
Same author

Modulating inflammasome (NLRP3) activation and stress granule (SG) formation: Insight of neuroprotection by Normobaric oxygen (NBO) in ischemic stroke.

Experimental neurology·2026

Related Experiment Video

Updated: Feb 10, 2026

A Coupled Experiment-finite Element Modeling Methodology for Assessing High Strain Rate Mechanical Response of Soft Biomaterials
11:28

A Coupled Experiment-finite Element Modeling Methodology for Assessing High Strain Rate Mechanical Response of Soft Biomaterials

Published on: May 18, 2015

13.0K

Soft Biomaterial-based Nanocrystal in Pharmaceutical.

Nandi Chen1,2, Taojunfeng Su3, Zhe Cheng3

  • 1Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY 10065, United States.

Current Pharmaceutical Design
|May 17, 2018
PubMed
Summary

Bio-soft materials offer advantages like biodegradation and water solubility for drug nanocrystal development. This review analyzes their properties and applications, aiding future research in this biomedical field.

Keywords:
Nanocrystalalbuminferritinnucleic acidpeptideprotein.

More Related Videos

Accessing the Cytotoxicity and Cell Response to Biomaterials
09:46

Accessing the Cytotoxicity and Cell Response to Biomaterials

Published on: July 8, 2021

4.6K
Fabrication of Spherical and Worm-shaped Micellar Nanocrystals by Combining Electrospray, Self-assembly, and Solvent-based Structure Control
06:16

Fabrication of Spherical and Worm-shaped Micellar Nanocrystals by Combining Electrospray, Self-assembly, and Solvent-based Structure Control

Published on: February 11, 2018

20.4K

Related Experiment Videos

Last Updated: Feb 10, 2026

A Coupled Experiment-finite Element Modeling Methodology for Assessing High Strain Rate Mechanical Response of Soft Biomaterials
11:28

A Coupled Experiment-finite Element Modeling Methodology for Assessing High Strain Rate Mechanical Response of Soft Biomaterials

Published on: May 18, 2015

13.0K
Accessing the Cytotoxicity and Cell Response to Biomaterials
09:46

Accessing the Cytotoxicity and Cell Response to Biomaterials

Published on: July 8, 2021

4.6K
Fabrication of Spherical and Worm-shaped Micellar Nanocrystals by Combining Electrospray, Self-assembly, and Solvent-based Structure Control
06:16

Fabrication of Spherical and Worm-shaped Micellar Nanocrystals by Combining Electrospray, Self-assembly, and Solvent-based Structure Control

Published on: February 11, 2018

20.4K

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Drug Delivery Systems

Background:

  • Bio-soft materials are increasingly used in biomedical research due to their biodegradability, solubility, and targeting capabilities.
  • These materials facilitate the generation and aggregation of drug nanocrystals.
  • Their unique properties make them valuable for biological and chemical applications.

Purpose of the Study:

  • To review the crucial design steps for bio-soft materials.
  • To analyze the emerging properties of bio-soft materials and their derivatives.
  • To discuss the application of bio-soft materials in drug nanocrystal development.

Main Methods:

  • A comprehensive literature survey was conducted on bio-soft material development.
  • Data and figures from relevant studies were meticulously analyzed.
  • The review focused on bio-soft materials used in nanocrystal formation.

Main Results:

  • Detailed information on bio-soft materials used for nanocrystals was presented across three sections.
  • The advantages and disadvantages of various bio-soft materials and their derivatives were discussed.
  • Specific examples of bio-soft material applications in drug nanocrystal formation were highlighted.

Conclusions:

  • This review provides insights into the properties and applications of existing bio-soft materials.
  • It aids in understanding the development and analysis of bio-soft materials for biomedical applications.
  • The findings can guide future research in optimizing bio-soft material design and utilization.